IP Library Granted Patent US 10,316,001
Granted Patent B2
US 10,316,001 · App. 15/559,385 · Granted Jun 11, 2019

Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrohydro pyrimidine-5-carbonitrile

Inventors: Heiko Schirmer (Solingen, DE); Philipp Rubenbauer (Dusseldorf, DE); Birgit Keil (Dusseldorf, DE); Britta Olenik (Bottrop, DE)
Assignee: pH Pharma Co., Ltd.
C07D239/22C07C315/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,316,001
App. No.
15/559,385
Granted
Jun 11, 2019
Kind
B2
Abstract

The present invention concerns a new and improved method for preparation of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I), as well as the preparation and use of the crystal form (A) of (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluormethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile of formula (I).

Claims (46)

1. A compound of formula (I)

in crystal form (A), characterized in that X-ray diffraction pattern of the compound shows peak maxima of the 2 theta angle at 7.5, 12.4, 15.1, 18.5, 18.7, 22.9, 24.7 and 26.5.

2. A compound of formula (I)

in the crystal form (A), characterized in that the Raman spectrum of the compound shows band maxima at 3075, 2928, 2918, 2236, 2216, 1646, 1605, 1195 and 1004 cm −1 .

3. A method for preparing the compound of formula (I) in the crystal form (A) as described in claim 1 , comprising crystallizing the compound from an alcohol to provide a crystal paste, and heating the crystal paste to 50-80° C. with stirring for 2-5 hour at this temperature to provide the compound of formula (I) in the crystal form (A).

4. A pharmaceutical composition comprising the compound of formula (I) in the crystal form (A) as described in claim 1 in more than 90 wt. percent of the total quantity of the compound of formula (I).

5. A method for treating pulmonary hypertonia (PH), chronic obstructive lung diseases (COPD), acute lung injury (ALI), acute respiratory disease syndrome (ARDS), pulmonary emphysema, alpha-1-antitrypsin deficiency (AATD), cystic fibrosis (CF), or bronchiectasis, comprising administering an effective amount of the compound of formula (I) crystal form (A) as described in claim 1 .

6. A method for promoting wound healing, comprising administering an effective amount of the compound of formula (I) crystal form (A) as described in claim 1 .

7. A method for preparing a compound of formula (I)

comprising,

a) reacting a compound of formula (IX)

in the presence of a methylation agent and a base to form a compound of formula (XVI);

b) reacting the compound of formula (XVI) in the presence of a palladium catalyst and a secondary amine base to form a compound of formula (XXVI)

in which R 1 stands for methyl,

or

reacting the compound of formula (XVI) in the presence of a palladium catalyst and a second amine base to form a compound of formula (XXVI), in which R 1 stands for hydrogen;

c) reacting the compound of formula XXVI, in which R 1 stands for hydrogen or methyl, in the presence of a cinchona alkaloid and a solvent to form compounds of formulas (XXVIII) and (XXIX)

d) isolating the compound of formula (XXVIII);

e) reacting the compound of formula (XXVIII) in the presence of a strong acid to form a compound of formula (XXVII)

f) reacting the compound of formula (XXVII) in the presence of an allyl halide or sulfonate and a base to forma compound of formula (X)

g) reacting the compound of formula (X) in the presence of a methylation agent and a base to form a compound of formula (XXIII)

h) reacting the compound of formula (XXIII) in the presence of a palladium catalyst and a base to form a compound of formula (XXVII)

in which R 1 stands for methyl;

i) reacting the compound of formula (XXVII) in the presence of an activation reagent, to form a compound of formula (XIX)

and

j) reacting the compound of formula (XIX) in the presence of a dehydrating agent, to provide the compound of formula (I);

or optionally,

k) after reaction step c) isolating the compound of formula (XXIX);

l) reacting the compound of formula (XXIX) in the presence of a strong acid to form a compound for formula (XXX)

m) reacting the compound of formula (XXX) in the presence of an allyl halide or sulfonate and a base to form a compound of formula (XXXI)

n) reacting the compound of formula (XXXI) in the presence of a strong, non-nucleophilic base in a solvent and under simultaneous heating to form the racemate of formula (IX);

and

o) reacting the compound of formula (IX) to form the compound of formula (I).

8. The method of claim 7 , wherein R 1 in formulas (XXVI), (XXVII), (XXVIII) and (XXIX) is methyl.

9. The method of claim 7 , wherein R 1 in formulas (XXVI), (XXVII), (XXVIII) and (XXIX) is hydrogen.

10. The method of claim 7 wherein, after reaction step c), the compound of formula (XXIX) is isolated; the compound of formula (XXIX) is reacted in the presence of a strong acid to form a compound of formula (XXX); the compound of formula (XXX) is reacted in the presence of an allyl halide or sulfonate and a base to form a compound of formula (XXXI);

p) the compound of formula (XXXI) is reacted in the presence of a strong, non-nucleophilic base in a solvent and under simultaneous heating to form a racemate of formula (IX); and

the compound of formula (IX) is converted to the compound of formula (I).

11. The method of claim 7 further comprising crystallizing the compound of formula (I) in an alcohol to provide a crystal paste, heating the resulting crystal paste to 50-80° C., and stirring for 2-5 hours at this temperature to provide the compound of formula (I) in crystal form (A).

12. The method of claim 7 , wherein the cinchona alkaloid is chosen from the group consisting of quinine and quinidine.

13. The method of claim 7 wherein the solvent for reaction step c) is chosen from C 2 -C 5 alkyl esters of acetic acid, C 1 -C 6 alcohols and mixtures of C 1 -C 6 alcohols and waters.

14. The method of claim 7 wherein for reaction step c) for a compound of formula (XXVI) with R 1 =methyl, quinidine is used as the cinchona alkaloid and n-butyl acetate as the solvent, and for a compound of formula (XXVI) with R 1 =hydrogen, quinine is used as the cinchona alkaloid and a mixture of isopropanol and water is used as the solvent.

15. The method of claim 7 wherein dimethylsulfate is the methylation agent in step a).

16. The method of claim 7 wherein dimethylsulfate is the methylation agent and sodium bis(trimethylsilyl)amide is the base in step g).

17. The method of claim 7 wherein palladium acetate with triphenylphosphine as ligand is used as the palladium catalyst and morpholine is used as the secondary amine base in step b).

18. The method of claim 7 wherein palladium acetate with triphenylphosphine as ligand is used as the palladium catalyst and morpholine is used as the base in step h).

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 14, 2024
From: THE THEO GROUP
To: PEAK BIO, INC.
Reel/Frame 069263/0109 →
SECURITY INTEREST Recorded Jul 23, 2024
From: PEAK BIO, INC.
To: THE THEO GROUP
Reel/Frame 068057/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2019
From: SCHIRMER, HEIKO; RUBENBAUER, PHILIPP; KEIL, BIRGIT; OLENIK, BRITTA
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 048647/0628 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: PH PHARMA CO. LTD.
Reel/Frame 048239/0502 →
Priority Claims (1)
EP 15159570 · Mar 18, 2015 · regional
Continuity (1)
Related Publication 20180072685A1 · Mar 15, 2018